Neurobiology of the effects of hallucinogens and dissociative anesthetics;Neurobiologie účinku halucinogenů a disociativních anestetik

Psychiatrie

Volumn 12, Issue SUPPL. 3, 2008, Pages 33-45

  Páleníček, Tomáš ^a   Horáček, Jiří ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

5 HT2A receptor; Antipsychotics; Dissociative anesthetics; Dopamin; Glutamate; Hallucinogens; Ketamine; LSD; Mescaline; NMDA; Noradrenalin; Phencyclidine; Psilocybin; Serotonin

Indexed keywords

ANESTHETIC AGENT; DIZOCILPINE; ERGOLINE DERIVATIVE; INDOLEAMINE; KETAMINE; MESCALINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; PHENETHYLAMINE DERIVATIVE; PSILOCYBINE; PSYCHEDELIC AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

CHEMICAL STRUCTURE; COGNITIVE DEFECT; CONFERENCE PAPER; DISSOCIATION; DOPAMINERGIC ACTIVITY; DRUG MECHANISM; EMOTIONAL DISORDER; HUMAN; MENTAL DISEASE; MONOAMINERGIC SYSTEM; NERVE CELL; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PERCEPTION DISORDER; SCHIZOPHRENIA;

EID: 55349114376     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (221)

1. Abel KM, Allin MP, Hemsley DR, Geyer MA. Low dose ketamine increases prepulse Inhibition in healthy men. Neuropharmacology 2003;44:729-737.
2. Adams BW, Bradberry CW, Moghaddam B. NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. Synapse 2002;43:12-18.
3. Adams BW, Moghaddam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 2001;50:750-757.
4. Adams LM, Geyer MA. A proposed animal model for hallucinogens based on LSD's effects on patterns of exploration in rats. Behav Neurosci 1985a;99:881-900.
5. Adams LM, Geyer MA. Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Prog Neuropsychopharmacol Biol Psychiatry 1985b;9:121-132.
6. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999;156:1646-1649.
7. Aghajanian GK. Psychotogenic drug action on chemically defined neurons. Psychopharmacol Bull 1975;11:53.
8. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology 1999;21:16S-23S.
9. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 2000;31:302-312.
10. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA: Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 2005;55:242-251.
11. Anden NE, Corrodi H, Fuxe K. Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons. J Pharmacol Exp Ther 1971;179:236-249.
12. Anden NE, Corrodi H, Fuxe K, Hokfelt T. Evidence for a central 5-hydroxy-tryptamine receptor stimulation by lysergic acid diethylamide. Br J Pharmacol 1968;34:1-7.
13. Antkiewicz-Michaluk L, Romanska I, Vetulani J. Ca2+ channel blockade prevents lysergic acid diethylamide-induced changes in dopamine and serotonin metabolism. Eur J Pharmacol 1997;332:9-14.
14. Appel JB, West WB, Rolandi WG, Alici T, Pechersky K. Increasing the selectivity of drug discrimination procedures. Pharmacol Biochem Behav 1999;64:353-358.
15. Arvanov VL, Liang X, Magro P, Roberts R, Wang RY. A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci 1999a;11:2917-2934.
16. Arvanov VL, Liang X, Russo A, Wang RY. LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex. Eur J Neurosci 1999b;11:3064-3072.
17. Baldridge EB, Bessen HA. Phencyclidine. Emerg Med Clin North Am 1990;8:541-550.
18. Baron SP, Woods JH. Competitive and uncompetitive N-methyl-D-aspartate antagonist discriminations in pigeons: CGS 19755 and phencyclidine. Psychopharmacology (Berl) 1995;118:42-51.
19. Benneyworth MA, Smith RL, Sanders-Bush E. Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist. Neuropsychopharmacology 2008;33:2206-2216.
20. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 2007;72:477-484.
21. Boothman LJ, Sharp T. A role for midbrain raphe gamma aminobutyric acid neurons in 5-hydroxytryptamine feedback control. Neuroreport 2005;16:891-896.
22. Bortolozzi A, az-Mataix L, Scorza MC, Celada P, Arrigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 2005;95:1597-1607.
23. Bubenikova V, Votava M, Horacek J, Palenicek T, Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 2005;80:591-596.
24. Bubenikova-Valesova V, Horacek J, Palenicek T. The effect of serotonin receptors on deficits in PPI induced by MK-801. World J Biol Psychiatry 2005;6 (Suppl. 1):328.
25. Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008;32:1014-1023.
26. Bubenikova-Valesova V, Votava M, Palenicek T, Horacek J. The opposite effect of a low and a high dose of serotonin-1A agonist on behavior induced by MK-801. Neuropharmacology 2007;52:1071-1078.
27. Bubenikova-Valesova V, Votava M, Palenicek T, Horacek J, Hoschl C. Effect of serotonin-1A receptor on behavioral changes in animal model of schizophrenia-like behavior. European Psychiatry 2008;23 (Suppl. 2): S61.
28. Burris KD, Breeding M, Sanders-Bush E. (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. J Pharmacol Exp Ther 1991;258:891-896.
29. Callado LF, Hopwood SE, Hancock PJ, Stamford JA. Effects of dizocilpine (MK 801) on noradrenaline, serotonin and dopamine release and uptake. Neuroreport 2000;11:173-176.
30. Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, Waters N. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J Neural Transm 1999;106:123-129.
31. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. J Med Chem 2001;44:1003-1010.
32. Colpaert FC, Janssen PA. The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of putported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology 1983;22:993-1000.
33. Dai H, Gebhardt K, Carey RJ. Time course effects of MK-801: the relationship between brain neurochemistry and behavior. Brain Res Bull 1995;36:175-180.
34. Dall'Olio R, Gaggi R, Bonfante V, Gandolfi O. The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol 1999;10:63-71.
35. Davies MF, Deisz RA, Prince DA, Peroutka SJ. Two distinct effects of 5-hydroxytryptamine on single cortical neurons. Brain Res 1987;423:347-352.
36. Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 2000;35:53-61.
37. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 1998;31 Suppl 2:80-84.
38. Doherty MD, Pickel VM. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area Brain Res 2000;864:176-185.
39. Dulawa SC, Geyer MA. Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology 2000;39:2170-2179.
40. Duncan EJ, Madonick SH, Parwani A, Angrist B, Rajan R, Chakravorty S, Efferen TR, Szilagyi S, Stephanides M, Chappell PB, Gonzenbach S, Ko GN, Rotrosen JP. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 2001;25:72-83.
41. Eckler JR, Reissig CJ, Rabin RA, Winter JC. A 5-HT(2C) receptor-mediated interaction between 2,5-dimethoxy-4-methylamphetamine and citalopram in the rat. Pharmacol Biochem Behav 2004;79:25-30.
42. Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology (Berl) 1998;136:409-414.
43. Etou K, Kuroki T, Kawahara T, Yonezawa Y, Tashiro N, Uchimura H. Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex. Pharmacol Biochem Behav 1998;61:427-434.
44. Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl) 2005;181:496-503.
45. Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH. Hallucinogen-like actions of 5-methoxy-N,N- diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 2006;83:122-129.
46. Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol 2008;75:17-33.
47. Fone KC, Johnson JV, Bennett GW, Marsden CA. Involvement of 5-HT2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CG 3509) to rats. Br J Pharmacol 1989;96:599-608.
48. GADDUM JH. Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J Physiol 1953;121:15P.
49. Geter-Douglass B, Witkin JM. Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice. Psychopharmacology (Berl) 1997;133:43-50.
50. Gewirtz JC, Marek GJ. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 2000;23:569-576.
51. Geyer MA, Light RK, Rose GJ, Petersen LR, Horwitt DD, Adams LM, Hawkins RL. A characteristic effect of hallucinogens on investigatory responding in rats. Psychopharmacology (Berl) 1979;65:35-40.
52. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005;95:434-441.
53. Gleason SD, Shannon HE. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 1997;129:79-84.
54. Glennon RA, Titeler M, Lyon RA. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol Biochem Behav 1988;30:597-601.
55. Glennon RA, Young R, Jacyno JM, Slusher M, Rosecrans JA. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur J Pharmacol 1983;86:453-459.
56. Gobert A, Millan MJ. Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 1999;38:315-317.
57. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007;53:439-452.
58. Gorzalka BB, Hill MN, Sun JC. Functional role of the endocannabinoid system and AMPA/kainate receptors in 5-HT2A receptor-mediated wet dog shakes. Eur J Pharmacol 2005;516:28-33.
59. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar KA, Sass H, Geyer MA: Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol 1998;9:561-566.
60. Gouzoulis-Mayfrank E, Hermle L. Are the "Entactogens" a distinct psychoactive substance class? The contribution of human experimental studies to the classification of MDMA and other chemically related methylenedioxyamphetamine derivates. The Heffter Review of Psychedelic Research 1998;46-51.
61. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Bull U, Sass H. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 1999;20:565-581.
62. Grace AA. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can altet basal ganglia function. Drug Alcohol Depend 1995;37:111-129.
63. Gresch PJ, Smith RL, Barrett RJ, Sanders-Bush E: Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex. Neuropsychopharmacology 2005;30:1693-1702.
64. Gresch PJ, Strickland LV, Sanders-Bush E. Lysergic acid diethylamide-induced Fos expression in rar brain: role of seroronin-2A receptors. Neuroscience 2002;114:707-713.
65. Hasler F, Bourquin D, Brenneisen R, Bar T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-aceric acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 1997;72:175-184.
66. Heekeren K, Neukirch A, Daumann J, Stoll M, Obradovic M, Kovar KA, Geyer MA, Gouzoulis-Mayfrank E. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J Psychopharmacol 2007;21:312-320.
67. Helsley S, Fiorella D, Rabin RA, Winter JC. A comparison of N,N-dimethyltryptamine, harmaline, and selected congeners in rats trained with LSD as a discriminative stimulus. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:649-663.
68. Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992;32:976-991.
69. Hermle L, Gouzoulis-Mayfrank E, Spitzer M. Blood flow and cerebral laterality in the mescaline model of psychosis. Pharmacopsychiatry 1998;31 Suppl 2:85-91.
70. Hillegaart V, Estival A, Ahlenius S. Evidence for specific involvement of 5-HT1A and 5-HT2A/C receptors in the expression of patterns of spontaneous motor activity of the rat. Eur J Pharmacol 1996;295:155-161.
71. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20:389-409.
72. Horáček J. Neurobiologie působení halucinogenních látek. Adiktologie 2005;5:134-150.
73. Hutson PH, Barton CL, Jay M, Blurton P, Burkamp F, Clarkson R, Bristow LJ: Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT(2C/2B) receptor antagonists: neurochemical and behavioural studies. Neuropharmacology 2000;39:2318-2328.
74. Ichikawa J, Dai J, Meltzer HY: DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res 2001;907:151-155.
75. Jakab RL, Goldman-Rakic PS. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A 1998;95:735-740.
76. Jakab RL, Goldman-Rakic PS. Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol 2000;417:337-348.
77. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20:201-225.
78. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 2002;7:837-844.
79. Katayama T, Jodo E, Suzuki Y, Hoshino KY, Takeuchi S, Kayama Y. Activation of medial prefrontal cortex neurons by phencyclidine is mediated via AMPA/kainate glutamate receptors in anesthetized rats. Neuroscience 2007;150:442-448.
80. Kaur P, Ahlenius S. Potentiation of DOI-induced forward locomotion in rats by (-)-pindolol pretreatment. J Neural Transm 1997;104:605-614.
81. Kaur P, Ahlenius S. Non-serotonergic potentiation by (-)-pindolol of DOI-induced forward locomotion in rats: possible involvement of beta-adrenoceptots? J Neural Transm 2000;107:903-917.
82. Klodzinska A, Bijak M, Tokarski K, Pile A. Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav 2002;73:327-332.
83. Krebs-Thomson K, Geyer MA. The role of 5-HT(1A) receptors in the locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI and LSD in rats. Behav Pharmacol 1996;7:551-559.
84. Krebs-Thomson K, Paulus MP, Geyer MA. Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 1998;18:339-351.
85. Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA. The roles of 5-HT(1A) and 5-HT (2) receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl) 2006;189:319-329.
86. Krystal JH, D'Souza DC, Karper LP, Bennett A, bi-Dargham A, bi-Saab D, Cassello K, Bowers MB, Jr., Vegso S, Heninger GR, Charney DS. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 1999a;145:193-204.
87. Krystal JH, D'Souza DC, Petrakis IL, Beiger A, Berman RM, Charney DS, bi-Saab W, Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999b;7:125-143.
88. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE. Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 2003;304:229-237
89. Kurova M, Fujakova M, Palenicek T, Bubenikova-Valesova V. Srovnání účinku psychedelik mezkalinu a 2C-B vanimálním modelu - role serotoninových 5-HT2 a 5-HT1 receptorů. Psychiatrie 2008;12 (Suppl. 1): 47.
90. Kutova M, Palenicek T, Fujakova M. Role serotoninových 5-HT1 a 5-HT2 receptorů v mechanizmu účinku synterické drogy 2C-B. Psychiarrie 2007;11 (Suppl. 2): 44-45.
91. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteets. Neuropsychopharmacology 2001;25:455-467.
92. Lambe EK, Aghajanian GK. Prefrontal cortical network activity: Opposite effects of psychedelic hallucinogens and D1/D5 dopamine receptor activation. Neuroscience 2007;145:900-910.
93. Lambe EK, Goldman-Rakic PS, Aghajanian GK. Serotonin induces EPSCs preferentially in layer V pyramidal neurons of the frontal cortex in the rat. Cereb Cortex 2000;10:974-980.
94. Lanfumey L, Hamon M. 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:1-10.
95. Leng A, Ouagazzal A, Feldon J, Higgins GA: Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol Biochem Behav 2003;75:281-288.
96. Leysen JE. 5-HT2 receptors. Curr Drug Targets CNS Neural Disord 2004;3:11-26.
97. Li JX, Rice KC, France CP. Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys. J Pharmacol Exp Ther 2008;324:827-833.
98. Lindefors N, Barati S, O'Connor WT. Differential effects of single and repeated ketamine administtation on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res 1997;759:205-212.
99. Liu R, Jolas T, Aghajanian G. Serotonin 5-HT(2) receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res 2000;873:34-45.
100. Lopez-Gil X, Babot Z, margos-Bosch M, Sunol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefronral cortex of the rat. Neuropsychopharmacology 2007;32:2087-2097.
101. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003;117:697-706.
102. Luby Ed, Cohen Bd, Rosenbaum G, Gottlieb Js, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 1959;81:363-369.
103. Maeng S, Zarate CA, Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007;9:467-474.
104. Maeng S, Zarate CA, Jr., Du J, Schloesser RJ, McCammon J, Chen G, Manji HK: Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349-352.
105. Maj J, Rogoz Z, Skuza G, Wedzony K: The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. J Neural Transm 1996;103:131-146.
106. Mansbach RS, Geyer MA. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 1989;2:299-308.
107. Marek GJ, Aghajanian GK. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther 1996;278:1373-1382.
108. Marek GJ, Aghajanian GK. Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Drug Alcohol Depend 1998a;51:189-198.
109. Marek GJ, Aghajanian GK. The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis. Biol Psychiatry 1998b;44:1118-1127.
110. Marek GJ, Wright RA, Gewirtz JC, Schoepp DD. A major role for thalamocortical afferents in serotonergic hallucinogen receptot function in the rat neocortex. Neuroscience 2001;105:379-392.
111. Marek GJ, Wright RA, Schoepp DD. 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 teceptor agonist LY354740. Neurosci Lett 2006;403:256-260.
112. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 2000;292:76-87.
113. Marona-Lewicka D, Nichols DE. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol Biochem Behav 2007;87:453-461.
114. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR, Jr., Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a- octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 2007;320:486-496.
115. Martin P, Waters N, Waters S, Carlsson A, Carlsson ML. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur J Pharmacol 1997;335:107-116.
116. Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G, Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through aglutamate-dependent mechanism. J Neurosci 2001;21:9856-9866.
117. Mathe JM, Nomikos GG, Blakeman KH, Svensson TH. Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity. Neuropharmacology 1999;38:121-128.
118. Mathe JM, Nomikos GG, Schilstrom B, Svensson TH. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res 1998;51:583-592.
119. Millan MJ, Dekeyne A, Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998a;37:953-955.
120. Millan MJ, Schreiber R, Dekeyne A, Rivet JM, Bervoets K, Mavridis M, Sebban C, Maurel-Remy S, Newman-Tancredi A, Spedding M, Muller O, Lavielle G, Brocco M: S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential anti-psychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison co clozapine and haloperidol. J Pharmacol Exp Ther 1998b;286:1356-1373.
121. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG: Dopamine receptors: from structute to function. Physiol Rev 1998;78:189-225.
122. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptot blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-2927.
123. Moghaddam B, Adams BW.Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281:1349-1352.
124. Musacchio JM, Klein M, Canoll PD. Dextromethorphan sites, sigma receptors, and the psychotomimetic effects of sigma opiates. Prog Clin Biol Res 1990;328:13-16.
125. Muschamp JW, Regina MJ, Hull EM, Winter JC, Rabin RA. Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex. Brain Res 2004;1023:134-140.
126. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T. Phencyclidine-induced head-twitch response in rats treated chronically with methysergide. Eur J Pharmacol 1987a;133:319-328.
127. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T. Phencyclidine-induced head-twitch responses as 5-HT2 receptor-mediated behavior in rats. Neurosci Lett 1987b;76:335-338.
128. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T. Phencyclidine-induced head-weaving observed in mice after ritanserin treatment. Eur J Pharmacol 1987c;139:171-178.
129. Nabeshima T, Yamaguchi K, Ishikawa K, Furukawa H, Kameyama T. Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats. J Pharmacol Exp Ther 1987d;243:1139-1146.
130. Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 1986;18:305-313.
131. Nichols DE. LSD and Its Lysergamide Cousins. The Heffter Review of Psychedelic Research 2001;2:80-87.
132. Nichols DE. Hallucinogens. Pharmacol Ther 2004;101:131-181.
133. Nichols DE, Monte A, Huang X, Marona-Lewicka D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav Brain Res 1996;73:117-119.
134. Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician 2007;10:493-500.
135. Oranje B, Gispen-de Wied CC, Verbaten MN, Kahn RS. Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol. Biol Psychiatry 2002;52:887-895.
136. Ouagazzal A, Grortick AJ, Moreau J, Higgins GA. Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 2001;25:565-575.
137. Oye I, Paulsen O, Maurset A.Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-asparrate receptors. J Pharmacol Exp Ther 1992;260:1209-1213.
138. Padich RA, McCloskey TC, Kehne JH. 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology (Berl) 1996;124:107-116.
139. Palenicek T, Balikova M, Bubenikova-Valesova V, Horacek J. Mescaline effects on rat behaviot and its time profile in serum and brain tissue after a single subcutaneous dose. Psychopharmacology (Berl) 2008;196:51-62.
140. Palenicek T, Bubenikova V, Votava M, Horacek J. Účinky MDMA, LSD a psilocinu na lokomoci potkana. Adiktologie 2005;5:121-130.
141. Palenicek T, Bubenikova-Valesova V. Effects of 5-HT2C and 5-HT2A receptor antagonism on hyperlocomocion induced by MK-801. World J Biol Psychiatry 2005;6 (Suppl. 1): 325-326.
142. Palenicek T, Bubenikova-Valesova V, Horacek J. Modeling of psychotic-like behavior: comparison of MK-801 with psilocin, LSD, mescaline and 2C-B models. Behavioral study on prepulse inhibition of acoustic starrle and on locomotion. Schizophrenia Research 2006a;8 (Suppl.): 292.
143. Palenicek T, Bubenikova-Valesova V, Horacek J. Modeling of psychotic-like behavior: comparison of MK-801 with psilocin, LSD, mescaline and 2C-B models. Behavioral study on prepulse inhibition of acoustic startle and on locomotion. Schizophrenia Research 2006b;81 (Suppl.): 292.
144. Palenicek T, Bubenikova-Valesova V, Horacek J. Srovnání nové syntetické drogy 2C-B súčinky klasických psychedelik (LSD, psilocin, mezkalin) a MDMA vanimálním modelu. Psychiatrie 2006c;10 (Suppl. 1): 23.
145. Palenicek T, Bubenikova-Valesova V, Horacek J. Srovnání amfetaminu, ketaminu, MK-801, meskalinu, psilocinu, LSD a 2C-B v animálním modelu schizofrenie. Psychiatrie 2007a;11 (Suppl. 2): 61-62.
146. Palenicek T, Bubenikova-Valesova V, Horacek J. Srovnání amfetaminu, ketaminu, MK-801, meskalinu, psilocinu, LSD a 2C-B v animálním modelu schizofrenie. Psychiatrie 2007b;11 (Suppl. 2): 61-62.
147. Palenicek T, Bubenikova-Valesova V, Horacek J. The role of seroronin 5-HT2A/C receptors in the behavioral action of the synthetic drug 2C-B. World J Biol Psychiarry 2007c;8 (Suppl. 1):205.
148. Palenicek T, Bubenikova-Valesova V, Horacek J, Vrajova M, Novak T. Účinky selektivního antagonisty serotoninového 5-HT2C receproru SB242084 na lokomoci potkana v animálních modelech psychóz. Psychiatrie 2006;10:16-20.
149. Palenicek T, Bubenikova-Valesova V, Vales K, Horacek J, Vrajova M. Role 5-HT1A a 5-HT2A/C receprorů v mechanismu účinku syntetické drogy Nexus (2C-B) - animální studie na potkanech. Nemocná duše - nemocný mozek: klinická zkušenost a fakta 2006d;150.
150. Palenicek T, Fujakova M, Kutova M, Brunovsky M, Horacek J, Bubenikova-Valesova V. Behavioral and QEEG effects of the psychedelic drug 4-bromo-2,5-dimethoxyphenylethylamine (2C-B) in rats - a possible model of psychosis? Behavioural Pharmacology 2007e;18 (Suppl. 1): S13.
151. Palenicek T, Fujakova M, Kutova M, Brunovsky M, Horacek J, Bubenikova-Valesova V. Behavioral and QEEG effects of the psychedelic drug 4-bromo-2,5-dimethoxyphenylethylamine (2C-B) in rats - a possible model of psychosis? Behavioural Pharmacology 2007d;18 (Suppl. 1): S13.
152. Palenicek T, Hlinak Z, Bubenikova-Valesova V, Horacek J. Pohlavní rozdíly vúčinku psychedelik LSD a Psilocinu u potkana vtestu otevřeného pole. Psychiatrie 2007f;11(Suppl. 1): 43.
153. Palenicek T, Hlinak Z, Bubenikova-Valesova V, Votava M, Horacek J: An analysis of sponraneous behavior following acute MDMA treatment in male and female rats. Neuro Endocrinol Lett 2007a;28:781-788.
154. Palenicek T, Horacek J, Bubenikova-Valesova V, Stastny F. The effect of specific ligands of 5-HT/DA receptors on locomotion in MK-801-treated animals. Physiological Research 2003;52 (3): 36P.
155. Palenicek T, Rohanova M, Balikova M, Horacek J. Behavioral Effects of 2C-B in Rats - study on prepulse inhibition of acoustic startle and locomotion - a preliminary report. Proceedings from ICADS /Tiaft 2007 (http:// wwwicadts2007org) 2007b.
156. Pehek EA, McFarlane HG, Maguschak K, Price B, Pluto CP. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res 2001;888:51-59.
157. Pehek EA, Nocjar C, Roth BL, Byrd TA, Mabrouk OS. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 2006;31:265-277.
158. Penington NJ. Actions of methoxylated amphetamine hallucinogens on serotonergic neurons of the brain. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:951-965.
159. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ: Functional characterization of agonists at recombinant human
160. Pozzi L, Acconcia S, Ceglia I, Invernizzi RW, Samanin R Stimulation of 5-hvdroxytryptamine (5-HT(2C)) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem 2002;82:93-100.
161. Pranzatelli MR, Pluchino RS. The relation of central 5-HT1A and 5-HT2 receptors: low dose agonist-induced selective tolerance in the rat. Pharmacol Biochem Behav 1991;39:407-413.
162. Rabiner EA. Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen? J Psychopharmacol 2007;21:253-258.
163. Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, Grewal JS, Garnovskaya MN. Multiplicity of mechanisms of serotonin receptor signal ttansduction. Pharmacol Ther 2001;92:179-212.
164. Riba J, Rodriguez-Fornells A, Barbanoj MJ. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology (Berl) 2002;165:18-28.
165. Robson L, Gower AJ, Kendall DA, Marsden CA. Age-related behavioural, neurochemical and radioligand binding changes in the central 5-HT system of Sprague-Dawley rats. Psychopharmacology (Berl) 1993;113:274-281.
166. Rodriguez de FF, Del A, I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 2005;40:2-14.
167. Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology (Berl) 1989;98:495-499.
168. Sanders-Bush E, Breeding M. Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs. Psychopharmacology (Berl) 1991;105:340-346.
169. Schmidt CJ, Fadayel GM. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther 1996;277:1541-1549.
170. Schreiber R, Lowe D, Voerste A, De VJ. LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol 2000;388:R3-R4.
171. Scruggs JL, Patel S, Bubser M, Deutch AY. DOI-induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons. J Neurosci 2000;20:8846-8852.
172. Scruggs JL, Schmidt D, Deutch AY. The hallucinogen 1-[2,5-dimethoxy-4- iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neurosci Lett 2003;346:137-140.
173. Seeman P, Ko F, Tallerico T. Dopamine recepror contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 2005;10:877-883.
174. Seeman P, Lasaga M. Dopamine agonist action of phencyclidine. Synapse 2005;58:275-277.
175. Shah NS, Hedden MP Behavioral effects and metabolic fate of N,N-dimethyltryptamine in mice pretreared with beta-diethylaminoethyl- diphenylpropylacetate (SKF 525-A), improniazid and chlorpromazine. Pharmacol Biochem Behav 1978;8:351-356.
176. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 2001;24:330-334.
177. Shin EJ, Lee PH, Kim HJ, Nabeshima T, Kim HC. Neuropsychotoxicity of abused drugs: potential of dextromethorphan and novel neuroprotective analogs of dextromethorphan with improved safety profiles in terms of abuse and neuroprotective effects. J Pharmacol Sci 2008;106:22-27.
178. Shulgin A, Shulgin A. Pihkal . A Chemical Love Story. Berkley, CA: Transform Press 1991.
179. Shulgin A, Shulgin A. Tihkal. The continuation. 1st ed. Berkeley, CA: Transform Press 1997.
180. Shulgin AT. Mescaline: the chemistry and pharmacology of its analogs. Lloydia 1973;36:46-58.
181. Shulgin AT, Carter MF. Centrally active phenethylamines. Psychopharmacol Commun 1975;1:93-98.
182. Silva MT, Calil HM. Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia 1975;42:163-171.
183. Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol 2008;313-333.
184. Sipes TA, Geyer MA. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 1994;33:441-448.
185. Sipes TE, Geyer MA. DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 1997;761:97-104.
186. Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 2007;52:279-290.
187. Smith RL, Barrett RJ, Sanders-Bush E. Mechanism of tolerance development to 2,5-dimethoxy-4-iodoamphetamine in rats: down-regulation of the 5-HT2A, but not 5-HT2C, receptor. Psychopharmacology (Berl) 1999;144:248-254.
188. Smith RL, Barrett RJ, Sanders-Bush E. Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice. Psychopharmacology (Berl) 2003;166:61-68.
189. Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 1996;73:121-124.
190. Titelet M, Lyon RA, Glennon RA: Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl) 1988;94:213-216.
191. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD. The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 1989;167:127-135.
192. Trulson ME, Heym J, Jacobs BL: Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats. Brain Res 1981;215:275-293.
193. Van OD, Megens A, Meert T, Luyten WH, Leysen JE. Role of 5-HT(2) receptors in the tryptamine-induced 5-HT syndrome in rats. Behav Pharmacol 2002;13:313-318.
194. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2- methylpropyio xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006;317:910-918.
195. Varty GB, Bakshi VP, Geyer MA. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 1999;20:311-321.
196. Varty GB, Higgins GA. Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. Eur J Pharmacol 1995;287:201-205.
197. Vollenweider FX. The use of psychomimetics in schizophrenia research with special emphasis on the PCP/ketamine model psychosis. SUCHT 1992;398-409.
198. Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on ptepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 2007;32:1876-1887.
199. Vollenweider FX, Gamma A, Vollenweider-Scherpenhuyzen MFI. Neural correlates of hallucinogen-induced altered states of consciousness. In: Hameroff, S. R., Kaszniak, A. W., and Chalmers, D. J., eds. Toward a Science of Consciousness III: The Third Tucson Discussions and Debates. Cambridge: MIT Press, 2002; 99-110.
200. Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natutal and drug-induced psychoses. Brain Res Bull 2001;56:495-507.
201. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997a;7:9-24.
202. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997b;16:357-372.
203. Vollenweider FX, Vontobel P, Hell D, Leenders KL: 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man - a PET study with [11C]raclopride. Neuropsychopharmacology 1999;20:424-433.
204. Wedzony K, Mackowiak M, Zajaczkowski W, Fijal K, Chocyk A, Czyrak A. WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 2000;23:547-559.
205. White PF, Way WL, Trevor AJ. Ketamine - its pharmacology and therapeutic uses. Anesthesiology 1982;56:119-136.
206. Wiley JL, Harvey SA, Balster RL, Nicholson KL. Affinity and specificity of N-methyl-D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats. Psychopharmacology (Berl) 2003;165:378-385.
207. Williams MT, Herring NR, Schaefer TL, Skelton MR, Campbell NG, Lipton JW, McCrea AE, Vorhees CV. Alterations in body temperature, corticosterone, and behavior following the administration of 5-methoxy-diisopropyltryptamine (,foxy') to adult rats: a new drug of abuse. Neuropsychopharmacology 2007;32:1404-1420.
208. Willins DL, Deutch AY, Roth BL. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997;27:79-82.
209. Winter JC. Antagonism of phencyclidine-induced stimulus control in the rat by other psychoactive drugs. Pharmacol Biochem Behav 2008;88:189-195.
210. Winter JC, Doat M, Rabin RA.Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia. Life Sci 2000;68:337-344.
211. Winter JC, Eckler JR, Rabin RA. Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology (Berl) 2004;172:233-240.
212. Winter JC, Rice KC, Amorosi DJ, Rabin RA. Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav 2007;87:472-480.
213. Wolff K, Winstock AR. Ketamine: from medicine to misuse. CNS Drugs 2006;20:199-218.
214. Yamaguchi K, Nabeshima T, Ishikawa K, Yoshida S, Kameyama T. Phencyclidine-induced head-weaving and head-twitch through interaction with 5-HT1 and 5-HT2 receptors in reserpinized rats. Neuropharmacology 1987;26:1489-1497.
215. Yamamoto T, Ueki S. The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs. Pharmacol Biochem Behav 1981;14:89-95.
216. Yan QS. Activation of 5-HT2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission. Brain Res Bull 2000;51:75-81.
217. Yan QS, Reith ME, Jobe PC, Dailey JW. Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 1997;765:149-158.
218. Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in tteatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-864.
219. Zeilhofer HU, Swandulla D, Geisslinger G, Brune K. Differential effects of ketamine enantiomers on NMDA receptor cutrents in cultured neurons. Eur J Pharmacol 1992;213:155-158.
220. Zhang C, Marek GJ. Group III metabotropic glutamate receptot agonists selectively suppress excitatory synaptic currents in the rat ptefrontal cortex induced by 5-hydroxytryptamine2A receptor activation. J Pharmacol Exp Ther 2007;320:437-447.
221. Zhang C, Marek GJ. AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:62-71.